TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32386362

Group type: EXPERIMENTAL
Intervention: Measures aimed at optimizing motor activity of students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological-hygienic standards of motor activity
Number of subjects: 0
Study: 33631500

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg, orally once daily in the morning)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (orally once daily in the morning)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 35268027

Group type: EXPERIMENTAL
Intervention: High NO3- (2 × 70 mL beetroot juice/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Medium NO3- (70 mL beetroot juice/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low NO3- (70 mL beetroot juice on alternate days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (70 mL of NO3--depleted beetroot juice on alternate days)
Number of subjects: 62
Study: 33638735

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 455

Group type: COMPARATOR
Intervention: Lenvatinib
Number of subjects: 455
Study: 32209983

Group type: EXPERIMENTAL
Intervention: Ketone monoester drink ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate, 482 mg/kg body mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ketone monoester drink
Number of subjects: 11
Study: 33550228

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of high-intensity interval training and time-restricted eating
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 33060632

Group type: EXPERIMENTAL
Intervention: High dose BDP/F 100/6 two inhalations b.i.d. (n=31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: BUD/F 200/6 two inhalations b.i.d. (n=29)
Number of subjects: 60
Study: 34625396

Group type: EXPERIMENTAL
Intervention: Educational flyer and monthly HTN education messages for one year (Case group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no educational intervention)
Number of subjects: 0
Study: 33126100

Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA) intervention
Number of subjects: 50
Study: 32563496

Group type: EXPERIMENTAL
Intervention: Impaired left ventricle ejection fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left ventricle global longitudinal strain (GLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diastolic function grade
Number of subjects: 0
Study: 35638702

Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptom State (PASS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latent class analysis
Number of subjects: 0
Study: 34465144

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 36378058

Group type: EXPERIMENTAL
Intervention: Jiedu granule (JDG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 33002791

Group type: EXPERIMENTAL
Intervention: Healthy Eating And Lifestyle after Stroke (HEALS) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 35181450

Group type: EXPERIMENTAL
Intervention: SLIM setup
Number of subjects: 80
Study: 34682341

Group type: EXPERIMENTAL
Intervention: Digital self‐fitting tool
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional audiological fitting
Number of subjects: 19
Study: 32641137

Group type: EXPERIMENTAL
Intervention: Surgical resection of residual metastatic disease +/− the primary tumor
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-surgical group
Number of subjects: 53
Study: 34224256

Group type: EXPERIMENTAL
Intervention: Levothyroxine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32024584

Group type: EXPERIMENTAL
Intervention: CPAP + Behavioral Sleep Medicine (BSM) intervention targeting physical activity and eating behavior changes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with CPAP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPAP + BSM intervention
Number of subjects: 60
Study: 34807712

Group type: EXPERIMENTAL
Intervention: Cognitive fatigue group (mentally demanding motor task)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nonfatigued control group (undemanding motor task)
Number of subjects: 59
Study: 34836153

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei LTL1879
Number of subjects: 20
Study: 32942663

Group type: EXPERIMENTAL
Intervention: Active video games (AVG) combined with exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BKOOL cycling simulator
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ring Fit Adventures
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dance Mats
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Xbox Kinect
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AVG combined with multi-component exercise
Number of subjects: 45
Study: 35986325

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 50
Study: 32075817

Group type: EXPERIMENTAL
Intervention: ROC (n=95)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual care (n=83)
Number of subjects: 178
Study: 33592176

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily, with dose reductions to 40 mg and 20 mg allowed)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sunitinib (50 mg, 4 weeks on and 2 weeks off, with dose reductions to 37.5 mg and 25 mg allowed)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily, with dose reductions to 200 mg twice daily and 250 mg once daily allowed)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Savolitinib (600 mg daily, with dose reductions to 400 mg and 200 mg allowed)
Number of subjects: 147
Study: 32746775

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 36464853

Group type: EXPERIMENTAL
Intervention: Lenvatinib 18 mg/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lenvatinib 24 mg/day
Number of subjects: 152
Study: 33588696

Group type: EXPERIMENTAL
Intervention: Narrative patient testimonial
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fact-based information text
Number of subjects: 167
Study: 32358259

Group type: EXPERIMENTAL
Intervention: Optical biometer (IOLMaster 700)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Scheimpflug device (Pentacam)
Number of subjects: 93
Study: 34609378

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 32807151

Group type: EXPERIMENTAL
Intervention: Educational intervention (classroom lecture, pamphlet, educational text messages, educational pamphlets) conducted for 1 month in four sessions
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 110
Study: 34472020

Group type: EXPERIMENTAL
Intervention: Pre-commitment reminder alone (1 message, mid-October)
Number of subjects: 196486

Group type: EXPERIMENTAL
Intervention: Pre-commitment + loss frame messages
Number of subjects: 196486

Group type: EXPERIMENTAL
Intervention: Pre-commitment + gain frame messages
Number of subjects: 196486

Group type: EXPERIMENTAL
Intervention: Loss frame messages alone
Number of subjects: 196486

Group type: EXPERIMENTAL
Intervention: Gain frame messages alone
Number of subjects: 196486

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 196486
Study: 35442367

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 66
Study: 33625939

Group type: EXPERIMENTAL
Intervention: 25 mg of promethazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34730795

Group type: EXPERIMENTAL
Intervention: secukinumab 150/300 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study: 32475155

Group type: EXPERIMENTAL
Intervention: Whiteboard video for HCPs and trainees outlining strategies to communicate about weight
Number of subjects: 70
Study: 34570042

Group type: EXPERIMENTAL
Intervention: 24-week home-based walking program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study: 32188502

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 36410690

Group type: EXPERIMENTAL
Intervention: BaP‐Enjoying Family Life
Number of subjects: 72

Group type: COMPARATOR
Intervention: EPEC‐Being a Parent
Number of subjects: 72
Study: 34710590

Group type: EXPERIMENTAL
Intervention: Coaching intervention comprising team-based didactic instruction with live observation at a TRA-proficient lab, followed by a visit from a cardiologist and catheterization laboratory nurse coaching team.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32708938

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Rehabilitation (SR)
Number of subjects: 40
Study: 34994232

Group type: EXPERIMENTAL
Intervention: ASP8062 + alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ASP8062 alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 20
Study: 33141935

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediate provisionalization (Group A: n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Immediate implant placement with delayed provisionalization (Group B: n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study: 33770684

Group type: EXPERIMENTAL
Intervention: 20 mg finerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capillary plasma sampling
Number of subjects: 0
Study: 32607644

Group type: EXPERIMENTAL
Intervention: LCIG infusion plus three oral doses of placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: LCIG
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral immediate-release carbidopa/levodopa (LC-IR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: LC-IR
Number of subjects: 13
Study: 33278599

Group type: COMPARATOR
Intervention: S-1 (40-60 mg twice daily for 4 weeks on/2 weeks off for 1 year)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) (130 mg/m2 every 3 weeks for 6 months)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: SOX plus chemoradiotherapy (SOXRT) (45 Gy)
Number of subjects: 546
Study: 34601044

Group type: EXPERIMENTAL
Intervention: eAVG
Number of subjects: 477

Group type: COMPARATOR
Intervention: sAVG
Number of subjects: 477
Study: 33000465

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33402624

Group type: EXPERIMENTAL
Intervention: Minimal excavation and LSTR with triple antibiotic paste (TAP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional indirect pulp treatment with calcium hydroxide
Number of subjects: 42
Study: 34455578

Group type: EXPERIMENTAL
Intervention: Zone I (0 to 40 mm from the root apex)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zone II (40 to 80 mm from the root apex)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: miRNA expression
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Target genes of differentially expressed miRNAs in root zone II
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Expression of ptc-miR169d target NFYA3
Number of subjects: 6
Study: 34406235

Group type: EXPERIMENTAL
Intervention: Controlled long wavelength ray light regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (uncontrolled light regimen)
Number of subjects: 0
Study: 36084082

Group type: EXPERIMENTAL
Intervention: Biperiden for 10 days
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 312
Study: 33002377

Group type: EXPERIMENTAL
Intervention: Leg heat therapy (HT) 3 times/week for 6 weeks using water-circulating trousers at 48°C
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Leg heat therapy (HT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study: 35125434

Group type: EXPERIMENTAL
Intervention: SMART mHealth app intervention
Number of subjects: 34
Study: 34051211

Group type: EXPERIMENTAL
Intervention: MicroShunt
Number of subjects: 527

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 527
Study: 32892987

Group type: EXPERIMENTAL
Intervention: Single Antiplatelet Therapy (SAPT)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy (DAPT)
Number of subjects: 610
Study: 34337012

Group type: EXPERIMENTAL
Intervention: MMED+AFS+BMSCs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MMED+AFS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MMED
Number of subjects: 45
Study: 35854331

Group type: EXPERIMENTAL
Intervention: Coparenting-focused intervention (eight classes: four during and four following pregnancy)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 110
Study: 34142951

Group type: EXPERIMENTAL
Intervention: Generic metformin hydrochloride (850 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Glucophage (reference preparation)
Number of subjects: 36
Study: 32076783

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1767
Study: 32519394

Group type: EXPERIMENTAL
Intervention: Clipped sites
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unclipped sites
Number of subjects: 13
Study: 32564889

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by preoperative chemotherapy and surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36353406

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Procedural sedation (PS)
Number of subjects: 43
Study: 32464334

Group type: EXPERIMENTAL
Intervention: 4-valent HPV vaccine (6/11/16/18)
Number of subjects: 3817

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3817
Study: 36431312

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation and intensive one-to-one training (NEURO®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional NEURO® occupational therapy
Number of subjects: 0
Study: 32053984

Group type: EXPERIMENTAL
Intervention: Walnut group (1, 1.5, or 2 oz. of walnuts daily)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Control group (habitual diet, no walnuts or tree nuts)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Walnut group
Number of subjects: 698

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 698
Study: 36178527

Group type: EXPERIMENTAL
Intervention: Hug robotic transfer support device
Number of subjects: 0
Study: 35438586

Group type: EXPERIMENTAL
Intervention: Integrated Behavior Therapy for Children with Selective Mutism (IBTSM)
Number of subjects: 30
Study: 33152122

Group type: EXPERIMENTAL
Intervention: levosimendan
Number of subjects: 2385

Group type: COMPARATOR
Intervention: epinephrine
Number of subjects: 2385

Group type: COMPARATOR
Intervention: dopexamine
Number of subjects: 2385

Group type: COMPARATOR
Intervention: enoximone
Number of subjects: 2385

Group type: COMPARATOR
Intervention: dopamine-milrinone
Number of subjects: 2385
Study: 35114491

Group type: EXPERIMENTAL
Intervention: BEMER® blanket
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo blanket
Number of subjects: 12

Group type: COMPARATOR
Intervention: No blanket
Number of subjects: 12
Study: 34153979

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study: 32451241

Group type: EXPERIMENTAL
Intervention: ACTitouch adaptive compression therapy (ACT) system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Multilayered bandage (MLB) compression systems
Number of subjects: 56
Study: 36041341

Group type: EXPERIMENTAL
Intervention: Low-fidelity model
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-fidelity model (cadaver)
Number of subjects: 62
Study: 34491021

Group type: EXPERIMENTAL
Intervention: Kynurenic acid 0.5% (FS2) cream (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active onion extract comparator treatment (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive vehicle (Group 3)
Number of subjects: 0
Study: 32026257

Group type: COMPARATOR
Intervention: Remifentanil at 0 ng·ml‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil at 1 ng·ml‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil at 3 ng·ml‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil at 5 ng·ml‐1
Number of subjects: 40
Study: 35818033

Group type: EXPERIMENTAL
Intervention: Remote data collection (caregiver weight, child height and weight)
Number of subjects: 38
Study: 35531914

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) to 33°C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted normothermia (37.5°C)
Number of subjects: 0
Study: 32050055

Group type: EXPERIMENTAL
Intervention: Naltrexone HCl (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nalmefene HCl (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 35947827

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pimavanserin (in subgroup analysis)
Number of subjects: 18
Study: 33773103

Group type: EXPERIMENTAL
Intervention: Buprenorphine plus naloxone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral for methadone maintenance therapy
Number of subjects: 0
Study: 33227793

Group type: EXPERIMENTAL
Intervention: CAABMR group
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 365
Study: 34951474

Group type: EXPERIMENTAL
Intervention: Warrior Programme intervention (Time Line Therapy™)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 32961529

Group type: EXPERIMENTAL
Intervention: Double-balloon band with ipsilateral ulnar artery compression (group 2)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Single-bladder radial compression band (group 1)
Number of subjects: 253
Study: 36109438

Group type: EXPERIMENTAL
Intervention: Office bleaching
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home bleaching
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group for office bleaching
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group for home bleaching
Number of subjects: 180
Study: 32888826

Group type: EXPERIMENTAL
Intervention: 2.5mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 161
Study: 32506233

Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 33472052

Group type: EXPERIMENTAL
Intervention: Catheter ablation-based AF rhythm control with optimal HF therapy and aggressive catheter ablation (PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Rate control with optimal HF therapy and measures to achieve resting HR < 80 bpm and 6-minute walk HR < 110 bpm
Number of subjects: 600
Study: 33275775

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg elemental selenium daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 90
Study: 33023544

Group type: EXPERIMENTAL
Intervention: Unmet need for contraception
Number of subjects: 386

Group type: COMPARATOR
Intervention: Age 20-24 years
Number of subjects: 386

Group type: COMPARATOR
Intervention: Age 30 years and above
Number of subjects: 386

Group type: COMPARATOR
Intervention: Uneducated women
Number of subjects: 386

Group type: COMPARATOR
Intervention: Unaware of family planning
Number of subjects: 386

Group type: COMPARATOR
Intervention: Not previously practiced contraception
Number of subjects: 386
Study: 35377385

Group type: EXPERIMENTAL
Intervention: Breastfeeding educational intervention along with standard care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 33781372

Group type: EXPERIMENTAL
Intervention: HRV study group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Tabata high‐intensity control group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vinyasa yoga low‐intensity control group
Number of subjects: 134
Study: 35029187

Group type: EXPERIMENTAL
Intervention: antihypertensive drugs + acupuncture
Number of subjects: 158

Group type: COMPARATOR
Intervention: antihypertensive drugs + sham acupuncture
Number of subjects: 158
Study: 34440352

Group type: EXPERIMENTAL
Intervention: Concentric muscle work (CMW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Eccentric muscle work (EMW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Concentric‐eccentric muscle work (C‐EMW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isometric muscular work (IMW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ACTN3 RR genotype
Number of subjects: 80
Study: 36207870

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 140